Breaking
Who am I? Plus today's other quizzes Roast chicken, congee and cookies: Ravinder Bhogal’s autumn squash recipes LIV Golf secures potential $300m investment Nobel prize in physics goes to Francis Halzen for south pole work on neutrinos Gassiev unsure if Fury v Joshua will be for his WBA belt Stop worrying about my AI, says multibillionaire Sam Altman. So we bear the risks and he keeps the money | Chris Stokel-Walker Cristiano Ronaldo accuses Portugal coach Jorge Jesus of broken promises How AI decision models could change content moderation Republican John James seeks some distance from Trump in Michigan governor debate Battle of ideas looming in British politics, Badenoch to say
NEWSREEL
The day, in 30-second reels.
--:--:--
World / Reel
World · Video brief

After new drug’s ‘unprecedented’ results for pancreatic cancer, doctors look at other uses

A revolutionary drug, daraxonrasib, is changing the landscape of pancreatic cancer treatment by doubling survival times. Initially trialed at UCLA, it's showing promise beyond just pancreatic cancer, with the FDA fast-tracking its approval....

NBC News· May 31, 2026 · 1:29 PM · 40 views

Video won't play? Watch on YouTube →

A revolutionary drug, daraxonrasib, is changing the landscape of pancreatic cancer treatment by doubling survival times. Initially trialed at UCLA, it's showing promise beyond just pancreatic cancer, with the FDA fast-tracking its approval. Doctors and patients alike are eagerly anticipating its potential to redefine cancer therapy. #CancerResearch #PancreaticCancer #MedicalBreakthrough #FDAApproval #Oncology

Originally reported by NBC News. Read the full story →

More in World

World World
World

Roast chicken, congee and cookies: Ravinder Bhogal’s autumn squash recipes

The Guardian· 39 minutes ago
World World
World

Republican John James seeks some distance from Trump in Michigan governor debate

NBC News· 2 hours ago
World World
World

Battle of ideas looming in British politics, Badenoch to say

BBC News· 2 hours ago

0 Comments

No comments yet. Be the first.